<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-159950" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Sevelamer</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kharsa</surname>
            <given-names>Antoine</given-names>
          </name>
          <aff>American University of Beirut</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rout</surname>
            <given-names>Preeti</given-names>
          </name>
          <aff>Wilson Case Western University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Antoine Kharsa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Rout declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>14</day>
          <month>9</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-159950.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">Chronic kidney disease (CKD) is a complex condition that poses significant challenges, profoundly affecting patients' quality of life and mortality. This&#x000a0;impact is secondary to numerous manifestations stemming from the progressive decline in glomerular filtration rate and its associated consequences.<xref ref-type="bibr" rid="article-159950.r1">[1]</xref>&#x000a0;In advanced CKD, phosphate clearance decreases, leading to its accumulation in the body.<xref ref-type="bibr" rid="article-159950.r2">[2]</xref>&#x000a0;While some phosphate originates endogenously, most is absorbed through the gastrointestinal (GI) tract. The concept of using phosphate binders emerged in the mid-twentieth century, with various agents such as aluminum-based, calcium-based, and lanthanum-based binders being used. However, due to adverse effects, particularly in the CKD population, the search for more effective medications continued.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>The US Food and Drug Administration (FDA) has approved sevelamer, a nonabsorbable, polymer-based phosphate binder, for managing hyperphosphatemia in patients with CKD and aged 6 and older.<xref ref-type="bibr" rid="article-159950.r3">[3]</xref><xref ref-type="bibr" rid="article-159950.r4">[4]</xref> The Kidney Disease Improving Global Outcomes (KDIGO) 2017 clinical practice guidelines recommend using phosphate binders to manage hyperphosphatemia in CKD patients stages 3 to 5. Sevelamer is included among the recommended phosphate binders for this purpose.<xref ref-type="bibr" rid="article-159950.r5">[5]</xref>&#x000a0;The&#x000a0;KDIGO 2023 guidelines continue to endorse this practice outlined in the 2017 guidelines for managing hyperphosphatemia.</p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Sevelamer is used off-label in pediatrics to pretreat oral or enteral nutrition formulas, such as expressed breast milk or cow's milk, to reduce phosphate burden in individuals with hyperphosphatemia due to renal disease.<xref ref-type="bibr" rid="article-159950.r6">[6]</xref>&#x000a0;Additionally, sevelamer may help lower serum lipid levels, potentially due to its ability to chelate bile acids within the GI tract.<xref ref-type="bibr" rid="article-159950.r7">[7]</xref></p>
      </sec>
      <sec id="article-159950.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Sevelamer is a calcium- and metal-free phosphate-binding agent that works within the intraluminal&#x000a0;GI&#x000a0;tract&#x000a0;to&#x000a0;effectively bind dietary phosphate and reduce its absorption.<xref ref-type="bibr" rid="article-159950.r8">[8]</xref>&#x000a0;Sevelamer exists in 2 forms&#x02014;sevelamer hydrochloride and sevelamer&#x000a0;carbonate.&#x000a0;The&#x000a0;primary difference between these forms is their respective effects on serum bicarbonate levels.</p>
        <p>Sevelamer hydrochloride lowers serum bicarbonate by releasing a hydrochloride molecule when binding to phosphate, which can contribute to acidosis&#x02014;a condition frequently encountered in patients with CKD. Hence,&#x000a0;certain formulations of sevelamer hydrochloride were withdrawn from the US market in October 2009.<xref ref-type="bibr" rid="article-159950.r9">[9]</xref>&#x000a0;Sevelamer carbonate does not exhibit this effect.<xref ref-type="bibr" rid="article-159950.r10">[10]</xref></p>
        <p>The polymeric amine structure of sevelamer has&#x000a0;been shown to effectively bind bile acids, which is a well-established mechanism for reducing serum total and low-density lipoprotein cholesterol (LDL-C). This mechanism is similar to that of bile acid-binding resins, which also lower cholesterol levels.<xref ref-type="bibr" rid="article-159950.r9">[9]</xref><xref ref-type="bibr" rid="article-159950.r11">[11]</xref>&#x000a0;Clinical trials with sevelamer hydrochloride have consistently demonstrated a significant reduction in total cholesterol levels, from 15% to 30%. However, triglycerides, high-density lipoprotein (HDL) cholesterol, and albumin levels remain unaltered.<xref ref-type="bibr" rid="article-159950.r9">[9]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Sevelamer is not absorbed systemically, and its primary site of action occurs within the intraluminal space of the GI tract.</p>
        <p><bold>Distribution:</bold> Sevelamer&#x000a0;is not distributed in the body due to its nonabsorbable nature.</p>
        <p><bold>Metabolism:</bold>&#x000a0;Sevelamer is a nonabsorbable medication, so it does not undergo metabolism within the body.</p>
        <p><bold>Elimination:</bold>&#x000a0;Sevelamer&#x000a0;is excreted unchanged in the feces.<xref ref-type="bibr" rid="article-159950.r12">[12]</xref></p>
      </sec>
      <sec id="article-159950.s3" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Sevelamer is administered orally, with therapy initiation requiring consideration of the patient's prior exposure to phosphate binders, distinguishing between those who are phosphate binder-naive and those already receiving treatment.<xref ref-type="bibr" rid="article-159950.r9">[9]</xref>&#x000a0;The medication is orally administered concomitantly with meals and is available in&#x000a0;2 distinct formulations&#x02014;tablets and suspension powder.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Tablet: Available as 400 mg (sevelamer hydrochloride only)&#x000a0;and&#x000a0;800 mg (sevelamer carbonate or sevelamer hydrochloride).</p>
          </list-item>
          <list-item>
            <p>Suspension powder: Available in packets for oral suspension in 800 mg or 2400 mg (sevelamer carbonate only).</p>
          </list-item>
        </list>
        <p>The dosing equivalence between sevelamer carbonate and sevelamer hydrochloride is maintained on a milligram-to-milligram basis. Therefore, when transitioning between these formulations, keeping the same prescribed dosage is recommended.<xref ref-type="bibr" rid="article-159950.r9">[9]</xref></p>
        <p>Finally, when considering tablet formulations, it is important to avoid crushing or smashing pills, especially in patients with dysphagia, as this can significantly increase the risk of aspiration and complications. Tablets should also not be crushed for administration via nasogastric or other enteral tubes due to the risk of tube occlusion. However, one study suggests that crushing pills might be feasible under certain conditions.<xref ref-type="bibr" rid="article-159950.r13">[13]</xref></p>
        <p>Sevelamer hydrochloride tablets are indicated for controlling serum phosphorus in patients with CKD who are on dialysis. However, the safety and efficacy of these tablets in CKD patients who are not on dialysis have not been studied.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p><bold>Management of hyperphosphatemia in patients with&#x000a0;chronic kidney disease:&#x000a0;</bold>For phosphate binder-naive patients, the initial dosing is as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Serum&#x000a0;phosphate levels greater than 9 mg/dL: 1600&#x000a0;mg of sevelamer administered&#x000a0;orally 3 times daily with meals.</p>
          </list-item>
          <list-item>
            <p>Serum phosphate levels between 7.5&#x000a0;and 9 mg/dL: 1200-1600 mg of sevelamer administered orally 3 times daily with meals.</p>
          </list-item>
          <list-item>
            <p>Serum phosphate levels between 5.5&#x000a0;and 7.5 mg/dL: 800 mg of&#x000a0;sevelamer administered&#x000a0;orally 3 times daily with meals.</p>
          </list-item>
        </list>
        <p>Dosage adjustments for sevelamer involve titrating the doses, with 400 to 800 mg increments per meal at 2-week intervals as required to attain the desired serum phosphorus levels. Clinical studies suggest that the average prescribed daily dose for adults is approximately 7.2 g.<xref ref-type="bibr" rid="article-159950.r9">[9]</xref>&#x000a0;The maximum daily dose studied in adult&#x000a0;CKD patients undergoing dialysis was 14 g.</p>
        <p><bold>Maintenance dosage:&#x000a0;</bold>The objective is to maintain a serum phosphate level of 5.5 mg/dL or lower.</p>
        <list list-type="bullet">
          <list-item>
            <p>Serum&#x000a0;phosphate levels for 5.5 mg/dL: The dosage of sevelamer should be increased by 400 to 800 mg per meal.</p>
          </list-item>
          <list-item>
            <p>Serum phosphate levels between 3.5 and 5.5 mg/dL: The current dosage of sevelamer should be continued.</p>
          </list-item>
          <list-item>
            <p>Serum phosphate less than 3.5 mg/dL: The dosage of&#x000a0;sevelamer should be decreased by 400 to 800 mg per meal.</p>
          </list-item>
        </list>
        <p><bold>Switching from calcium acetate:</bold>&#x000a0;When transitioning from calcium acetate to sevelamer, appropriate dosing adjustments are necessary to ensure effective management of hyperphosphatemia.</p>
        <list list-type="bullet">
          <list-item>
            <p>A dose of 800 mg of sevelamer hydrochloride or sevelamer&#x000a0;carbonate should be substituted for 667 mg of calcium acetate.</p>
          </list-item>
          <list-item>
            <p>A dose of 1600 mg of sevelamer hydrochloride or sevelamer&#x000a0;carbonate should be substituted for 1334 mg of calcium acetate.</p>
          </list-item>
          <list-item>
            <p>A dose of 2400 mg of sevelamer hydrochloride or sevelamer&#x000a0;carbonate should be substituted for 2001 mg of calcium acetate.<xref ref-type="bibr" rid="article-159950.r14">[14]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;No dosage adjustments are necessary.</p>
        <p><bold>Renal impairment:</bold>&#x000a0;No dosage adjustments are required, as sevelamer is not absorbed and does not necessitate changes in dosing for CKD patients, including those on hemodialysis or peritoneal dialysis.</p>
        <p><bold>Pregnancy considerations</bold>: No&#x000a0;dosage adjustment is needed. However, repletion of folic acid and fat-soluble vitamins may be necessary, as sevelamer can interfere with their absorption by binding bile acids.</p>
        <p><bold>Breastfeeding&#x000a0;considerations:</bold>&#x000a0;The administration&#x000a0;of sevelamer to lactating mothers does not lead to drug excretion in breast milk or cause any detrimental effects on the breastfed infant.<xref ref-type="bibr" rid="article-159950.r15">[15]</xref></p>
        <p><bold>Pediatric patients:</bold>&#x000a0;For off-label use in pediatric patients with CKD, sevelamer hydrochloride or sevelamer carbonate can be administered as pretreatment to lower phosphate levels before consuming dairy or breast milk. For this purpose,&#x000a0;800 mg of sevelamer hydrochloride or sevelamer carbonate (in tablet or powder form) should be mixed with up to 400 mL of breast milk, 100 mL of infant formula, tube feeding, or cow's milk. After the sevelamer is added, the mixture should be allowed to stand for 10 minutes before pouring off the liquid for feeding, leaving the sediment at the bottom. Clinical observations show reductions in phosphate levels of more than 85% in breast milk, 42% in cow's milk, 48% in tube feeding, and 68% in infant formula.<xref ref-type="bibr" rid="article-159950.r6">[6]</xref></p>
      </sec>
      <sec id="article-159950.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The primary GI adverse effects are attributed to sevelamer's action in the intraluminal space and its binding of phosphate and bile acids. Common adverse effects include gastrointestinal intolerance, vomiting, nausea, diarrhea, dyspepsia, abdominal pain, nasopharyngitis, limb pain, pruritus, arthralgia, and bronchitis.<xref ref-type="bibr" rid="article-159950.r16">[16]</xref><xref ref-type="bibr" rid="article-159950.r17">[17]</xref>&#x000a0;</p>
        <p>Other less commonly reported adverse effects include rash, flatulence, constipation, ileus, intestinal obstruction, intestinal perforation, worsening GI bleeding, necrosis, ulcers, and colitis.<xref ref-type="bibr" rid="article-159950.r18">[18]</xref><xref ref-type="bibr" rid="article-159950.r19">[19]</xref>&#x000a0;These adverse events warrant careful consideration, especially in populations at higher risk for these complications.<xref ref-type="bibr" rid="article-159950.r20">[20]</xref><xref ref-type="bibr" rid="article-159950.r21">[21]</xref><xref ref-type="bibr" rid="article-159950.r22">[22]</xref>&#x000a0;Notably, addressing constipation before initiating sevelamer treatment on patients is advisable.<xref ref-type="bibr" rid="article-159950.r9">[9]</xref><xref ref-type="bibr" rid="article-159950.r16">[16]</xref>&#x000a0;Metabolic acidosis may occur with sevelamer hydrochloride use. Additionally, some reports have noted an increased incidence of peritonitis in patients undergoing peritoneal dialysis who are prescribed sevelamer.<xref ref-type="bibr" rid="article-159950.r23">[23]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Healthcare providers should consider administering oral medications separately from sevelamer if decreased bioavailability might significantly impact the safety or effectiveness of the concurrent drugs (such as cyclosporine, tacrolimus, and levothyroxine). The duration of separation should be adjusted based on the absorption properties of the medications and whether they are immediate-release or extended-release. Close monitoring of the clinical response and blood concentrations of the concomitant medications is essential.</p>
        <p>The binding affinity of sevelamer to bile acids and oleic acid may affect the absorption of fat-soluble vitamins, such as A, D, E, and K. Therefore, it is advisable to consider appropriate supplementation, especially for individuals with CKD who need vitamin D.<xref ref-type="bibr" rid="article-159950.r24">[24]</xref></p>
      </sec>
      <sec id="article-159950.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>As with any medication, the presence of a hypersensitivity reaction to the drug, one of its components, or its formulation is a contraindication. Additionally, sevelamer is contraindicated in cases of bowel obstruction due to potential GI&#x000a0;adverse effects.<xref ref-type="bibr" rid="article-159950.r25">[25]</xref>&#x000a0;In addition, it is worth mentioning that the Canadian labeling of the medication contraindicates its use&#x000a0;in hypophosphatemia and&#x000a0;ulcerative colitis, GI bleeding,&#x000a0;perforation, and&#x000a0;necrosis.<xref ref-type="bibr" rid="article-159950.r18">[18]</xref><xref ref-type="bibr" rid="article-159950.r19">[19]</xref></p>
      </sec>
      <sec id="article-159950.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Serum biochemical parameters, including bicarbonate, calcium, phosphorus, parathyroid hormone (PTH), and chloride levels, should be regularly monitored.</p>
        <p>The frequency of measuring serum calcium, phosphorus, and PTH may vary based on the severity of abnormalities, the rate of CKD progression, and the administration of therapies for CKD-associated mineral and bone disorders.</p>
        <p>According to the KDIGO 2017 guidelines:</p>
        <list list-type="bullet">
          <list-item>
            <p>For CKD stages 3a to 3b, serum calcium and phosphate should be assessed every 6 to 12 months. The frequency of PTH levels should be measured based on baseline levels and CKD progression.</p>
          </list-item>
          <list-item>
            <p>For CKD stage 4, serum calcium and phosphate should be evaluated every 3 to 6 months, while PTH should be measured every 6 to 12 months.</p>
          </list-item>
          <list-item>
            <p>For CKD stage 5 and end-stage renal disease, serum calcium and phosphate should be monitored every 1 to 3 months, and PTH levels should be assessed every 3 to 6 months.</p>
          </list-item>
        </list>
        <p>Additionally, periodic assessments of 24-hour urinary calcium, phosphorus, magnesium, and alkaline phosphatase should be performed every 12 months or more frequently if PTH levels are elevated. Creatinine, blood urea nitrogen, albumin, and intact PTH should be monitored every 3 to 12 months, with the frequency adjusted based on the severity of CKD. In practice, these tests are often conducted more frequently.</p>
        <p>Monitoring of bicarbonate levels is recommended for patients receiving sevelamer hydrochloride, especially those with CKD who are not undergoing hemodialysis or are on peritoneal dialysis. A noncontrolled cross-sectional study found that 22% of patients on peritoneal dialysis experienced metabolic acidosis associated with the treatment.<xref ref-type="bibr" rid="article-159950.r26">[26]</xref></p>
      </sec>
      <sec id="article-159950.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Due to the nonsystemic nature of the mode of action of sevelamer, instances of systemic intoxication have not been reported. However, routine monitoring of phosphate levels is crucial for determining the necessity for dosage adjustments.&#x000a0;Notably, sevelamer bears a resemblance to other medications in appearance. A notable case report highlighted metformin intoxication caused by the visual similarity between metformin and sevelamer tablets.<xref ref-type="bibr" rid="article-159950.r12">[12]</xref><xref ref-type="bibr" rid="article-159950.r27">[27]</xref></p>
      </sec>
      <sec id="article-159950.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Hyperphosphatemia is a common complication in individuals with CKD, often resulting in adverse clinical outcomes. The use of phosphate binders is crucial in managing these complications. Sevelamer, a phosphate binder, has demonstrated superior efficacy in controlling phosphate levels compared to alternative binders, primarily due to its more favorable adverse effect profile that does not constrain its utility. However, vigilant monitoring of phosphate, calcium, bicarbonate, and&#x000a0;PTH levels is warranted during sevelamer therapy to ensure optimal patient outcomes and prevent potential complications.</p>
        <p>Clinicians should carefully review the patient's medical history before prescribing sevelamer, as it may lead to severe complications in those with GI disorders. Effective communication with other healthcare providers, such as nephrologists, gastroenterologists, and speech therapists (for dysphagia patients), is crucial to minimize these risks. A comprehensive interprofessional healthcare team must be actively involved in managing sevelamer therapy to ensure patient safety and therapeutic success.</p>
        <p>The primary care provider or nephrologist typically initiates sevelamer therapy. Nursing staff should possess a comprehensive understanding of the drug's adverse event profile and play a key role in monitoring both adverse effects and therapeutic efficacy during follow-up appointments. Pharmacists contribute by verifying dosages, recommending adjustments, performing medication reconciliation to prevent drug interactions, and suggesting alternative formulations when appropriate. When switching between different phosphate binders or various formulations of sevelamer, engaging pharmacy services is crucial to ensure accurate dosage adjustments. Notably, it is also important to emphasize that sevelamer tablets should not be crushed. If a patient is unable to take tablets, sevelamer powder packets may be an appropriate alternative.</p>
        <p>Through cohesive collaboration across various disciplines, optimal sevelamer therapy can be achieved while minimizing associated risks. This interprofessional approach ensures comprehensive care that addresses all aspects of the patient's condition, ultimately leading to improved clinical outcomes and an enhanced quality of life for individuals with CKD.</p>
      </sec>
      <sec id="article-159950.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=159950&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=159950">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/159950/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=159950">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-159950.s10">
        <title>References</title>
        <ref id="article-159950.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Vaidya</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Aeddula</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <chapter-title>Chronic Kidney Disease</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2024</year>
            <month>7</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">30571025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159950.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Rout</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jialal</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <chapter-title>Hyperphosphatemia</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">31869067</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159950.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bleyer</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Dillon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garrett</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kant</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Schoenfeld</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Teitelbaum</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Zeig</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Slatopolsky</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients.</article-title>
            <source>Am J Kidney Dis</source>
            <year>1999</year>
            <month>Apr</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>694</fpage>
            <page-range>694-701</page-range>
            <pub-id pub-id-type="pmid">10196011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159950.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mohammad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Berendt</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Carlin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Faustino</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of the In Vitro Efficacy of Sevelamer Hydrochloride and Sevelamer Carbonate.</article-title>
            <source>J Pharm Sci</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>105</volume>
            <issue>2</issue>
            <fpage>864</fpage>
            <page-range>864-875</page-range>
            <pub-id pub-id-type="pmid">26219932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159950.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomson</surname>
                <given-names>CRV</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Mann</surname>
                <given-names>JFE</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>TI</given-names>
              </name>
              <name>
                <surname>Cushman</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Furth</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Knoll</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pecoits-Filho</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tobe</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Lytvyn</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Tunnicliffe</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Howell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tonelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Earley</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ix</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Sarnak</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Management of Blood Pressure in Patients With Chronic Kidney Disease Not Receiving Dialysis: Synopsis of the 2021 KDIGO Clinical Practice Guideline.</article-title>
            <source>Ann Intern Med</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>174</volume>
            <issue>9</issue>
            <fpage>1270</fpage>
            <page-range>1270-1281</page-range>
            <pub-id pub-id-type="pmid">34152826</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159950.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raaijmakers</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Houkes</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Schr&#x000f6;der</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Willems</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Monnens</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Pre-treatment of dairy and breast milk with sevelamer hydrochloride and sevelamer carbonate to reduce phosphate.</article-title>
            <source>Perit Dial Int</source>
            <year>2013</year>
            <season>Sep-Oct</season>
            <volume>33</volume>
            <issue>5</issue>
            <fpage>565</fpage>
            <page-range>565-72</page-range>
            <pub-id pub-id-type="pmid">23636435</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159950.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marangon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lindholm</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stenvinkel</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Nonphosphate-binding effects of sevelamer--are they of clinical relevance?</article-title>
            <source>Semin Dial</source>
            <year>2008</year>
            <season>Sep-Oct</season>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>385</fpage>
            <page-range>385-9</page-range>
            <pub-id pub-id-type="pmid">18573137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159950.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramsdell</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Renagel: a new and different phosphate binder.</article-title>
            <source>ANNA J</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>346</fpage>
            <page-range>346-7</page-range>
            <pub-id pub-id-type="pmid">10633608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159950.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barna</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Kapoian</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>O'Mara</surname>
                <given-names>NB</given-names>
              </name>
            </person-group>
            <article-title>Sevelamer carbonate.</article-title>
            <source>Ann Pharmacother</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>127</fpage>
            <page-range>127-34</page-range>
            <pub-id pub-id-type="pmid">19955298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159950.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pai</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Shepler</surname>
                <given-names>BM</given-names>
              </name>
            </person-group>
            <article-title>Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.</article-title>
            <source>Pharmacotherapy</source>
            <year>2009</year>
            <month>May</month>
            <volume>29</volume>
            <issue>5</issue>
            <fpage>554</fpage>
            <page-range>554-61</page-range>
            <pub-id pub-id-type="pmid">19397463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159950.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeng</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients.</article-title>
            <source>Ren Fail</source>
            <year>2023</year>
            <month>Dec</month>
            <volume>45</volume>
            <issue>1</issue>
            <fpage>2210230</fpage>
            <pub-id pub-id-type="pmid">37272189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159950.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burke</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Incerti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Plone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Sevelamer hydrochloride (Renagel), a nonabsorbed phosphate-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>193</fpage>
            <page-range>193-8</page-range>
            <pub-id pub-id-type="pmid">11210401</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159950.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spilios</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Altshuler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Radparvar</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Safety and feasibility of crushing sevelamer tablets for enteral feeding tube administration.</article-title>
            <source>J Clin Pharm Ther</source>
            <year>2021</year>
            <month>Apr</month>
            <volume>46</volume>
            <issue>2</issue>
            <fpage>369</fpage>
            <page-range>369-372</page-range>
            <pub-id pub-id-type="pmid">33037822</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159950.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <collab>Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group</collab>
            <article-title>KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone&#x000a0;Disorder (CKD-MBD).</article-title>
            <source>Kidney Int Suppl (2011)</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-59</page-range>
            <pub-id pub-id-type="pmid">30675420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159950.r15">
          <label>15</label>
          <element-citation publication-type="book">
            <chapter-title>Sevelamer</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>6</month>
            <day>21</day>
            <pub-id pub-id-type="pmid">29999718</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159950.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ohyama</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Furukawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ohnishi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kasashima</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kawashima</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kayahara</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Sigmoid colon diverticula perforation associated with sevelamer hydrochloride administration: A case report.</article-title>
            <source>Ann Med Surg (Lond)</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>10</volume>
            <fpage>57</fpage>
            <page-range>57-60</page-range>
            <pub-id pub-id-type="pmid">27547398</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159950.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nambiar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pillai</surname>
                <given-names>UK</given-names>
              </name>
              <name>
                <surname>Devasahayam</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Oliver</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Karippot</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Colonic Mucosal Ulceration and Gastrointestinal Bleeding Associated with Sevelamer Crystal Deposition in a Patient with End Stage Renal Disease.</article-title>
            <source>Case Rep Nephrol</source>
            <year>2018</year>
            <volume>2018</volume>
            <fpage>4708068</fpage>
            <pub-id pub-id-type="pmid">29682371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159950.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chintamaneni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kuan</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Kermanshahi</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Hashash</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Hematochezia Associated with Sevalamer-Induced Mucosal Injury.</article-title>
            <source>ACG Case Rep J</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>1</volume>
            <issue>3</issue>
            <fpage>145</fpage>
            <page-range>145-7</page-range>
            <pub-id pub-id-type="pmid">26157856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159950.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePetris</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Images of the Month: Gastric Pneumatosis Due to Sevelamer-Mediated Necrosis.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>110</volume>
            <issue>6</issue>
            <fpage>799</fpage>
            <pub-id pub-id-type="pmid">26052763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159950.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bhayana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chandra</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Lower gastrointestinal bleeding: association with Sevelamer use.</article-title>
            <source>World J Gastroenterol</source>
            <year>2008</year>
            <month>Apr</month>
            <day>28</day>
            <volume>14</volume>
            <issue>16</issue>
            <fpage>2615</fpage>
            <page-range>2615-6</page-range>
            <pub-id pub-id-type="pmid">18442219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159950.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Byeon</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Myung</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>[Colonic Mass Secondary to Sevelamer-associated Rectal Ulcer].</article-title>
            <source>Korean J Gastroenterol</source>
            <year>2021</year>
            <month>Jun</month>
            <day>25</day>
            <volume>77</volume>
            <issue>6</issue>
            <fpage>305</fpage>
            <page-range>305-308</page-range>
            <pub-id pub-id-type="pmid">34158451</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159950.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okwara</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Gulati</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rustagi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Birg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hanson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Upper Gastrointestinal Bleeding of Unusual Causation.</article-title>
            <source>Dig Dis Sci</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>63</volume>
            <issue>10</issue>
            <fpage>2541</fpage>
            <page-range>2541-2546</page-range>
            <pub-id pub-id-type="pmid">30178284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159950.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kerschbaum</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>K&#x000f6;nig</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hausdorfer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rudnicki</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Sevelamer use and incidence of peritonitis in peritoneal dialysis.</article-title>
            <source>Wien Klin Wochenschr</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>123</volume>
            <issue>7-8</issue>
            <fpage>204</fpage>
            <page-range>204-8</page-range>
            <pub-id pub-id-type="pmid">21442203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159950.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Braunlin</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhorov</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Apruzzese</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Hook</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Smisek</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Mandeville</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Holmes-Farley</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Bile acid binding to sevelamer HCl.</article-title>
            <source>Kidney Int</source>
            <year>2002</year>
            <month>Aug</month>
            <volume>62</volume>
            <issue>2</issue>
            <fpage>611</fpage>
            <page-range>611-9</page-range>
            <pub-id pub-id-type="pmid">12110025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159950.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <article-title>Sevelamer: constipation and occlusion. Complications, sometimes fatal.</article-title>
            <source>Prescrire Int</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>95</issue>
            <fpage>111</fpage>
            <pub-id pub-id-type="pmid">18630352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159950.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramos</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Moreso</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Borras</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ponz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Buades</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Teixid&#x000f3;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Morey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vera</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Do&#x000f1;ate</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>de Arellano</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Barbosa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross-sectional study.</article-title>
            <source>Perit Dial Int</source>
            <year>2007</year>
            <season>Nov-Dec</season>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>697</fpage>
            <page-range>697-701</page-range>
            <pub-id pub-id-type="pmid">17984434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159950.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacob</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Garrick</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Recurrent lactic acidosis and hypoglycemia with inadvertent metformin use: a case of look-alike pills.</article-title>
            <source>Endocrinol Diabetes Metab Case Rep</source>
            <year>2018</year>
            <volume>2018</volume>
            <pub-id pub-id-type="pmid">29340159</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
